Mutated Dynamin Agents Protect Podocyte Barrier Integrity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for proteinuria, kidney diseases, and related conditions such as diabetes and cancer are inadequate in addressing the underlying proteolytic cleavage of dynamin by cathepsin L, leading to podocyte damage and ultrafiltration barrier disruption.
Innovation Solution
Administration of protease resistance agents, such as recombinant dynamin with mutations like L356Q, G358V or R725A, that resist cleavage by cathepsin L, inducing formation of actin stress fibers and multimeric structures, thereby protecting dynamin from proteolytic degradation and maintaining the integrity of the podocyte ultrafiltration barrier.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If dynamin is administered to treat proteinuria, then podocyte function is improved, but dynamin is degraded by cathepsin L proteolysis
Solution Approach 1:
The patent applies parameter changes by modifying the amino acid sequence of dynamin through site-directed mutagenesis. Specific mutations (L356Q, G358V, R725A) are introduced to alter the proteolytic cleavage sites and stability parameters of dynamin, making it resistant to cathepsin L degradation while preserving its podocyte protective function.
Solution Approach 2:
The patent converts the harmful effect of cathepsin L proteolysis into a benefit by designing dynamin mutants that are specifically resistant to this degradation pathway. The mutations enable dynamin to withstand proteolytic attack, transforming the previously damaging enzymatic activity into a selective pressure that identifies more stable dynamin variants for therapeutic use.
2Reliability
If protease resistance mutations are introduced in dynamin, then resistance to cathepsin L is improved, but GTP hydrolysis activity may be impaired
Solution Approach 1:
The patent applies local quality by introducing mutations at specific localized regions of the dynamin protein (residues 356, 358, and 725) that are involved in proteolytic cleavage sites. These localized modifications confer protease resistance without disrupting the overall structural integrity and functional domains of dynamin, including its GTP hydrolysis capability.
Solution Approach 2:
The patent changes specific chemical parameters at targeted amino acid positions to achieve protease resistance. The mutations alter the proteolytic cleavage site parameters (making them unrecognizable to cathepsin L) while carefully selecting substitutions that preserve the GTP binding and hydrolysis parameters of the enzyme.
3Reliability
If dynamin forms multimeric structures, then proteolytic cleavage resistance is improved, but formation of actin stress fibers may be affected
Solution Approach 1:
The patent applies preliminary action by pre-forming multimeric dynamin structures (tetramers and higher-order assemblies) before they encounter proteolytic degradation. This pre-assembly protects the proteolytically sensitive regions through steric shielding and conformational changes, while the multimeric structures subsequently facilitate proper actin stress fiber organization through coordinated membrane remodeling activity.
Solution Approach 2:
The patent creates composite functional units by forming multimeric assemblies of mutated dynamin proteins. These composite structures combine multiple subunits with protected proteolytic sites, creating a more stable and functionally robust complex that can effectively organize actin cytoskeleton while resisting degradation.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The dynamin protease resistance agents effectively prevent proteinuria by maintaining the integrity of the podocyte ultrafiltration barrier, reducing kidney damage, and potentially treating associated conditions like cancer by inhibiting metastasis and cognitive impairment.
Implementation Method 1
the proteolytic-cleavage resistant dynamin is resistant to cleavage by cathepsin L
Implementation Method 2
the administering of the dynamin protease resistance agent induces the formation of actin stress fibers in podocytes
Implementation Method 3
the dynamin protease resistance agent results in multimeric dynamin structures
Implementation Method 4
maintaining the integrity of the podocyte ultrafiltration barrier
Data Source
AI summary
This invention relates generally to the treatment of cathepsin or dynamin mediated diseases, such as proteinuria, cancer, and cognitive disease and related products. Diagnostic and other assays are also provided, as well as methods for podocyte cell gene transfer.